HUE066126T2 - Gyógyszerészeti termékek és IL-17 antitestek stabil folyékony készítményei - Google Patents

Gyógyszerészeti termékek és IL-17 antitestek stabil folyékony készítményei

Info

Publication number
HUE066126T2
HUE066126T2 HUE15823805A HUE15823805A HUE066126T2 HU E066126 T2 HUE066126 T2 HU E066126T2 HU E15823805 A HUE15823805 A HU E15823805A HU E15823805 A HUE15823805 A HU E15823805A HU E066126 T2 HUE066126 T2 HU E066126T2
Authority
HU
Hungary
Prior art keywords
antibodies
liquid compositions
pharmaceutical products
stable liquid
stable
Prior art date
Application number
HUE15823805A
Other languages
English (en)
Hungarian (hu)
Inventor
Susanne Joerg
Kathrin Serno-Schersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55135471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE066126(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE066126T2 publication Critical patent/HUE066126T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0023—Time-frequency-space
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/0051—Allocation of pilot signals, i.e. of signals known to the receiver of dedicated pilots, i.e. pilots destined for a single user or terminal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Signal Processing (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE15823805A 2014-12-22 2015-12-21 Gyógyszerészeti termékek és IL-17 antitestek stabil folyékony készítményei HUE066126T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462095210P 2014-12-22 2014-12-22

Publications (1)

Publication Number Publication Date
HUE066126T2 true HUE066126T2 (hu) 2024-07-28

Family

ID=55135471

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15823805A HUE066126T2 (hu) 2014-12-22 2015-12-21 Gyógyszerészeti termékek és IL-17 antitestek stabil folyékony készítményei

Country Status (31)

Country Link
US (6) US11801300B2 (enExample)
EP (4) EP4372005A3 (enExample)
JP (4) JP6770974B2 (enExample)
KR (4) KR102506173B1 (enExample)
CN (5) CN113855800A (enExample)
AR (1) AR103173A1 (enExample)
AU (1) AU2015370522B2 (enExample)
BR (1) BR112017013240A2 (enExample)
CA (1) CA2971800A1 (enExample)
CL (1) CL2017001638A1 (enExample)
CO (1) CO2017005950A2 (enExample)
DK (1) DK3237001T5 (enExample)
EA (1) EA033824B1 (enExample)
EC (1) ECSP17047155A (enExample)
ES (1) ES2976305T3 (enExample)
FI (1) FI3237001T3 (enExample)
HR (1) HRP20240253T1 (enExample)
HU (1) HUE066126T2 (enExample)
IL (4) IL322000A (enExample)
LT (1) LT3237001T (enExample)
MX (1) MX2017008412A (enExample)
PE (1) PE20170952A1 (enExample)
PH (1) PH12017500966A1 (enExample)
PL (1) PL3237001T3 (enExample)
PT (1) PT3237001T (enExample)
RS (1) RS65387B1 (enExample)
SG (1) SG11201703828VA (enExample)
SI (1) SI3237001T1 (enExample)
TN (1) TN2017000181A1 (enExample)
TW (1) TW201641104A (enExample)
WO (1) WO2016103153A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
US20190194311A1 (en) * 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
TW202348250A (zh) * 2017-07-24 2023-12-16 美商再生元醫藥公司 穩定化之抗體組合物及其製法
CN111344043A (zh) * 2017-11-02 2020-06-26 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CA3083971A1 (en) * 2017-11-30 2019-06-06 Bio-Thera Solutions, Ltd. Liquid formulation of humanized antibody for treating il-6 related diseases
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
US20210346380A1 (en) * 2018-12-25 2021-11-11 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an egfr inhibitor
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
RU2754760C2 (ru) * 2019-04-02 2021-09-07 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция анти-il17a антитела и ее применение
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CN110124030A (zh) * 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
EP4031570A1 (en) 2019-09-20 2022-07-27 Novartis AG Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
AU2020386669A1 (en) 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
WO2022113105A1 (en) * 2020-11-25 2022-06-02 Dr. Reddy's Laboratories Limited Stable therapeutic protein formulation and methods of making the same
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof
WO2022258045A1 (zh) * 2021-06-11 2022-12-15 山东先声生物制药有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN113999300B (zh) * 2021-12-13 2022-09-13 青岛润达生物科技有限公司 一种高效提取卵黄抗体的复合沉降剂及方法
CN114452383B (zh) * 2022-02-17 2023-06-06 中国中医科学院中药研究所 司库奇尤单抗在治疗糖尿病溃疡中的用途
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
KR20240141083A (ko) * 2023-03-17 2024-09-25 (주)셀트리온 안정한 약제학적 제제 및 완제의약품의 제조공정
WO2025071335A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-17 항체의 안정한 액상 제형
CN117883376B (zh) * 2024-03-14 2024-06-25 北京四环生物制药有限公司 含重组人白细胞介素-2的药物制剂及其制备方法

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE229810T1 (de) 1985-07-09 1987-11-05 Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire Beschuetzung von proteinen und aehnlichem.
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
DE69434418T2 (de) 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DK0762897T3 (da) 1994-06-02 2003-07-21 Elan Drug Delivery Ltd Fremgangsmåde til forebyggelse af aggregering af proteiner/peptider ved rehydratisering eller optøning
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
WO2000045790A2 (en) 1999-02-08 2000-08-10 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
AU3921600A (en) 1999-03-25 2000-10-09 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
US20030203451A1 (en) 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6923962B2 (en) 2000-04-10 2005-08-02 Dennis Cvitkovitch Signal peptides, nucleic acid molecules and methods for treatment of caries
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CZ304855B6 (cs) 2000-05-15 2014-12-10 F. Hoffmann-La Roche Ag Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
EP1299420B1 (de) 2000-07-05 2008-02-13 Bergter, Wolfgang, Dr. Zusammensetzung für pharmaka und kosmetika
US20040038878A1 (en) 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7060270B2 (en) 2001-11-02 2006-06-13 Diagenics International Corporation Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
AU2002354363A1 (en) 2001-12-04 2003-06-17 Mitsubishi Pharma Corporation Method of activating protein
AU2003223214B2 (en) 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
JP2006502116A (ja) 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
ES2326076T3 (es) 2002-12-20 2009-09-30 Mitsubishi Tanabe Pharma Corporation Procedimiento de proteccion de un grupo tiol en un anticuerpo.
AU2003291527A1 (en) 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
WO2004062689A1 (en) 2003-01-08 2004-07-29 Chiron Corporation Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
EP1713502A1 (de) 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20060122150A1 (en) 2004-09-30 2006-06-08 Argentieri Dennis C Pharmaceutical composition and method for treating a joint-capsule arthropathy
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047340A2 (en) 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
CA2595380A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
US7704503B2 (en) 2005-02-14 2010-04-27 Wyeth Llc Use of IL-17F in diagnosis and therapy of airway inflammation
US20080267946A1 (en) 2005-03-08 2008-10-30 Medigenes Co., Ltd Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody Against Tgf-Beta
DK1865986T3 (en) 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
CN101296706B (zh) 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
JP2009510046A (ja) 2005-09-30 2009-03-12 メドイミューン・リミテッド インターロイキン−１３抗体組成物
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
EP1986674A4 (en) 2006-02-13 2009-11-11 Nektar Therapeutics PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
CN101495136A (zh) 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品
EP2377887A1 (en) 2006-03-10 2011-10-19 Zymogenetics Inc Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
RU2008142359A (ru) 2006-03-28 2010-05-10 Ф.Хоффманн-Ля Рош Аг (Ch) Композиция человеческого моноклонального антитела к igf-1r
GEP20125628B (en) * 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
WO2007143701A2 (en) 2006-06-06 2007-12-13 Progenics Pharmaceuticals, Inc. Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2007261019A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
WO2008011571A1 (en) 2006-07-21 2008-01-24 Amgen Inc. Polypeptides with reduced susceptibility to oxidation and methods of making
US7846443B2 (en) 2006-08-11 2010-12-07 Schering Corporation Antibodies to IL-17A
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
WO2008029908A1 (fr) 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
CA2666492C (en) 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
FR2908999B1 (fr) 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
WO2008079890A1 (en) 2006-12-20 2008-07-03 Progenics Pharmaceuticals (Nevada), Inc. Hepatitis c virus (hcv) inhibitory monoclonal antibody and bindable ligand thereof
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
MX2009008096A (es) 2007-02-02 2009-08-07 Novartis Ag Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
CL2008000883A1 (es) 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008134659A2 (en) 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2150537A4 (en) 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2171449A2 (en) 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2009003096A2 (en) 2007-06-26 2008-12-31 Centocor, Inc. Il-17 mutein proteins, antibodies, compositions, methods and uses
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
JP2010531340A (ja) 2007-07-10 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー 新規処方物
WO2009015063A2 (en) 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009025763A2 (en) 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
CA2707986A1 (en) 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
BRPI0819688A2 (pt) 2007-12-14 2015-06-16 Amgen Inc Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
MX2010007767A (es) 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EA024654B1 (ru) 2008-04-29 2016-10-31 Эмджен Рисерч (Мьюник) Гмбх Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
JP5785077B2 (ja) 2008-08-05 2015-09-24 ワイス・エルエルシー 崩壊温度より高温での凍結乾燥
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010030670A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
MX2011003013A (es) 2008-09-19 2011-04-11 Pfizer Formulacion liquida estable de anticuerpos.
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
US20100092566A1 (en) 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
CN102224169A (zh) 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
US20110223169A1 (en) 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
CN104398471A (zh) 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US10117906B2 (en) 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
EP2396034A4 (en) 2009-02-10 2012-11-21 Shenogen Pharma Group Ltd ANTIBODIES AND METHODS FOR TREATING DISEASES ASSOCIATED WITH A STROGEN RECEPTOR
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
AR075998A1 (es) 2009-04-01 2011-05-11 Genentech Inc Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
US11738084B2 (en) 2009-04-20 2023-08-29 Susan Szathmary Compositions for transfection of biomolecules into cells
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US9539233B2 (en) 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
MX338775B (es) 2009-06-04 2016-05-02 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
WO2010148337A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
EP2453874A2 (en) 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
EP2473191B1 (en) 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
EA201270528A1 (ru) 2009-10-10 2012-12-28 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити Композиции цитокинов семейства il-17 и их применение
AU2010313304B2 (en) 2009-10-30 2015-08-20 Janssen Biotech, Inc. IL-17A antagonists
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CA2783715A1 (en) 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
IN2012DN06720A (enExample) 2010-01-15 2015-10-23 Kirin Amgen Inc
US20130011413A1 (en) 2010-02-03 2013-01-10 The University Of Tokyo Method and Pharmaceutical Composition for Treatment of Intestinal Disease
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
CA2792517C (en) 2010-03-09 2020-03-24 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US20130195868A1 (en) 2010-06-24 2013-08-01 Eleven Biotherapeutics, Inc. Treating surface of the eye disorders
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
NZ607615A (en) 2010-08-05 2015-03-27 Anaptysbio Inc Antibodies directed against il-17
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP2625199B1 (en) 2010-10-08 2017-11-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
HRP20251174T1 (hr) 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
EP4029881A1 (en) 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Subcutaneously administered anti-il-6 receptor antibody
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
EP2661448A4 (en) 2011-01-07 2015-09-16 Abbvie Inc ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF
CN103384682B (zh) 2011-01-14 2017-04-12 Ucb医药有限公司 结合il‑17a和il‑17f的抗体分子
JP5782279B2 (ja) 2011-01-20 2015-09-24 株式会社Ｓｃｒｅｅｎホールディングス 基板処理方法および基板処理装置
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
KR101875155B1 (ko) 2011-05-02 2018-07-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HUE037087T2 (hu) 2011-10-19 2018-08-28 Morphosys Ag IL17C antagonistái gyulladásos rendellenességek kezelésére
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
CA2951856A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
EP2783014A1 (en) 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
PT2822590T (pt) * 2012-03-07 2016-12-15 Lilly Co Eli Formulação de anticorpo de il-17
SG11201405475UA (en) * 2012-03-07 2014-10-30 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
KR20150010709A (ko) 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
DK2858670T3 (en) 2012-06-12 2018-10-22 Orega Biotech Antagonists of IL-17 isoforms and their applications
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
US20140147556A1 (en) 2012-11-27 2014-05-29 Elwha Llc Edible or inhalable compositions having antibodies and methods of use
EP2742855A1 (en) 2012-12-11 2014-06-18 Friedrich-Alexander-Universität Erlangen-Nürnberg Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition
US20160185847A1 (en) 2012-12-17 2016-06-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
DK2934582T3 (da) 2012-12-21 2020-02-24 Ichnos Sciences SA Anti-her2-antistofformulering
AU2014209994B2 (en) 2013-01-24 2017-03-16 Glaxosmithkline Intellectual Property Development Limited TNF-alpha antigen-binding proteins
AP2015008584A0 (en) 2013-02-08 2015-07-31 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
MY174679A (en) 2013-03-13 2020-05-06 Genentech Inc Formulations with reduced oxidation
KR20150132332A (ko) 2013-03-15 2015-11-25 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 저농도 항체 제형
CA2906101A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP2996717A4 (en) 2013-05-17 2016-11-23 Cedars Sinai Medical Center DIFFERENT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A-MODULATED INFLAMMATION AND FIBROSIS
EP3052092A2 (en) 2013-10-02 2016-08-10 Vectura Limited Method and apparatus
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3365011A1 (en) 2015-10-19 2018-08-29 Novartis AG Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
CN113876947A (zh) 2022-01-04
AR103173A1 (es) 2017-04-19
US20170368174A1 (en) 2017-12-28
CN107257692B (zh) 2021-11-19
US20250276062A1 (en) 2025-09-04
KR102506173B1 (ko) 2023-03-07
ES2976305T3 (es) 2024-07-29
TW201641104A (zh) 2016-12-01
US12485172B2 (en) 2025-12-02
CA2971800A1 (en) 2016-06-30
IL322000A (en) 2025-09-01
CL2017001638A1 (es) 2018-04-13
HRP20240253T1 (hr) 2024-05-10
EA201791422A1 (ru) 2017-10-31
IL310604A (en) 2024-04-01
US20240415961A1 (en) 2024-12-19
WO2016103153A1 (en) 2016-06-30
EP4559935A2 (en) 2025-05-28
KR102614921B1 (ko) 2023-12-19
IL252141A0 (en) 2017-07-31
SI3237001T1 (sl) 2024-06-28
JP2023113906A (ja) 2023-08-16
CN114452381A (zh) 2022-05-10
EP3237001A1 (en) 2017-11-01
CN114452380A (zh) 2022-05-10
EP3237001B1 (en) 2024-02-07
MX2017008412A (es) 2017-10-19
DK3237001T3 (da) 2024-04-15
BR112017013240A2 (en) 2018-02-06
US12485173B2 (en) 2025-12-02
EP4372005A3 (en) 2024-07-31
CN107257692A (zh) 2017-10-17
KR20230173742A (ko) 2023-12-27
US20240173404A1 (en) 2024-05-30
ECSP17047155A (es) 2019-02-28
JP6878524B2 (ja) 2021-05-26
SG11201703828VA (en) 2017-07-28
PH12017500966A1 (en) 2017-10-18
CO2017005950A2 (es) 2017-08-31
EA033824B1 (ru) 2019-11-29
IL287328B1 (en) 2024-03-01
PE20170952A1 (es) 2017-07-13
KR20250008977A (ko) 2025-01-16
JP2021119165A (ja) 2021-08-12
TN2017000181A1 (en) 2018-10-19
LT3237001T (lt) 2024-04-25
US12296008B2 (en) 2025-05-13
US20250295769A1 (en) 2025-09-25
JP6770974B2 (ja) 2020-10-21
PT3237001T (pt) 2024-04-16
EP4372005A2 (en) 2024-05-22
RS65387B1 (sr) 2024-04-30
JP2020011963A (ja) 2020-01-23
DK3237001T5 (da) 2024-10-14
AU2015370522A1 (en) 2017-06-01
AU2015370522B2 (en) 2018-05-10
EP4559935A3 (en) 2025-08-20
EP4559934A2 (en) 2025-05-28
EP4559934A3 (en) 2025-08-20
IL287328B2 (en) 2024-07-01
KR20230037677A (ko) 2023-03-16
PL3237001T3 (pl) 2024-06-24
IL252141B (en) 2021-12-01
US20250279860A1 (en) 2025-09-04
CN113855800A (zh) 2021-12-31
IL310604B1 (en) 2025-11-01
KR20170095878A (ko) 2017-08-23
CN114452380B (zh) 2025-10-17
FI3237001T3 (fi) 2024-03-22
IL287328A (en) 2021-12-01
KR102749243B1 (ko) 2025-01-03
JP2018502910A (ja) 2018-02-01
US11801300B2 (en) 2023-10-31

Similar Documents

Publication Publication Date Title
IL310604B1 (en) Pharmaceutical products and stable liquid preparations of IL-17 antibodies
IL282481A (en) A liquid pharmaceutical preparation
IL287947A (en) Viscosity reduction of pharmaceutical preparations
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL277241A (en) A liquid pharmaceutical preparation
IL249117A0 (en) A liquid pharmaceutical preparation
IL252871B (en) A liquid pharmaceutical preparation containing etanercept
GB201718468D0 (en) Stable liquid pharmaceutical compositions of bortezomb